Connect Biopharma Holdings Limited Financial Liabilities At Fair Value Through Profit Or Loss
Connect Biopharma Holdings Limited (CNTB) had Financial Liabilities At Fair Value Through Profit Or Loss of CNY 2.07 billion as of 2020-12-31, per its 20-F filed 2022-03-31.
Discontinued › Notes
ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLoss · last filed 2022-03-31
- 2020-12-31: Financial Liabilities At Fair Value Through Profit Or Loss 2.07B CNY.
| Period end | Financial Liabilities At Fair Value Through Profit Or Loss |
|---|---|
| 2020-12-31 | 2.07B CNY 20-F · filed 2022-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| HYPERION DEFI, INC. (HYPD) | United States | $0.065B | |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |